The Role of CD276 in Cancers.

Abstract

OBJECTIVE:

Aberrant expression of the immune checkpoint molecule, CD276, also known as B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe the role of CD276 in malignancies and its potential therapeutic effect.

DATA SOURCES:

Database including PubMed, EMbase, Cochrane Library, CNKI, and Clinical Trails.gov were searched for eligible studies and reviews. Study selection: Original studies and review articles on the topic of CD276 in tumors were retrieved.

RESULTS:

CD276 is an immune checkpoint molecule in the epithelial mesenchymal transition (EMT) pathway. In this review, we evaluated the available evidence on the expression and regulation of CD276. We also assessed the role of CD276 within the immune micro-environment, effect on tumor progression, and the potential therapeutic effect of CD276 targeted therapy for malignancies.

CONCLUSION:

CD276 plays an essential role in cell proliferation, invasion, and migration in malignancies. Results from most recent studies indicate CD276 could be a promising therapeutic target for malignant tumors.

• Authors: Shengzhuo Liu, Jiayu Liang, Zhihong Liu, Chi Zhang, Yang Wang, Alice Helen Watson, Chuan Zhou, Fan Zhang, Kan Wu, Fuxun Zhang, Yiping Lu, Xianding Wang
• Journal: Frontiers in oncology (Front Oncol) Vol. 11 Pg. 654684 ( 2021) ISSN: 2234-943X [Print] Switzerland
• PMID: 33842369 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Liu, Liang, Liu, Zhang, Wang, Watson, Zhou, Zhang, Wu, Zhang, Lu and Wang.